Detection of clinically significant prostate cancer following initial omission of biopsy in multiparametric MRI era
Uro-OncologyFurther Publications Urology
Related content
Uro-Oncology
Prostate cancer detection and complications of MRI-targeted prostate biopsy using cognitive registration, software-assisted image fusion or in-bore guidance: a systematic review and meta-analysis of comparative studies
Prostate Cancer Prostatic Dis
Falagario UG, Pellegrino F, Fanelli A, Guzzi F, Bartoletti R, Cash H, Pavlovich C, Emberton M, Carrieri G, Giannarini G
doi: 10.1038/s41391-024-00827-x
Uro-Oncology
The detection rate for prostate cancer in systematic and targeted prostate biopsy in biopsy-naive patients, according to the localization of the lesion at the mpMRI: A single-center retrospective observational study
Prostate
Massanova M, Barone B, Caputo VF, Napolitano L, Ponsiglione A, Del Giudice F, Ferro M, Lucarelli G, Lasorsa F, Busetto GM, Robertson S, Trama F, Imbimbo C, Crocetto F
doi: 10.1002/pros.24761
Uro-Oncology
Association of Baseline MRI PI-RADS Score With Prostate Cancer Active Surveillance Early Biopsy Reclassification: Data From the Michigan Urological Surgery Improvement Collaborative (MUSIC)
J Urol
Nandalur KR, Shen C, Zhao L, Al-Katib S, Lee J, Seifman B, Ye H, Ginsburg K, Quinn T, Nandalur S, George A, Gangwish D, Dhaliwal A, Erwin C, Young A, Albeer A, Hafron J
doi: 10.1097/JU.0000000000004117
COMMENTED
Uro-Oncology
Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
JAMA Oncol
Tilki D, Chen MH, Wu J, Huland H, Graefen M, Trock BJ, Han M, D'Amico AV
doi: 10.1001/jamaoncol.2025.0110
Further Publications Urology
Infectious complications following transperineal prostate biopsy with or without periprocedural antibiotic prophylaxis-a systematic review including meta-analysis of all comparative studies
Prostate Cancer Prostatic Dis
Wolff I, Büchner M, Hauner K, Wagenlehner F, Burchardt M, Abele-Horn M, Wullich B, Gilfrich C, Pilatz A, May M
doi: 10.1038/s41391-024-00934-9
Uro-Oncology
Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study
Eur Urol
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, Verholen F, Kuss I, Smith MR
doi: 10.1016/j.eururo.2024.03.036
Further Publications Urology
Role of enzalutamide in primary and recurrent non-metastatic hormone sensitive prostate cancer: a systematic review of prospective clinical trials
Prostate Cancer Prostatic Dis
Shelan M, Achard V, Appiagyei F, Mose L, Zilli T, Fankhauser CD, Zamboglou C, Mohamad O, Aebersold DM, Cathomas R
doi: 10.1038/s41391-024-00829-9
Uro-Oncology
Comparing Magnetic Resonance Imaging and Prostate-Specific Membrane Antigen-Positron Emission Tomography for Prediction of Extraprostatic Extension of Prostate Cancer and Surgical Guidance: A Prospective Nonrandomized Clinical Trial
J Urol
Bahler CD, Tachibana I, Tann M, Collins K, Swensson JK, Green MA, Mathias CJ, Tong Y, Yong C, Boris RS, Brocken E, Hutchins GD, Sims JB, Hill DV, Smith N, Ferari C, Love H, Koch MO
doi: 10.1097/JU.0000000000004032
Uro-Oncology
Peri-operative outcomes following radical prostatectomy in the setting of advanced prostate cancer
BJU Int
Simhal RK, Wang KR, Shah YB, Lallas CD, Shah MS, Chandrasekar T
doi: 10.1111/bju.16370